ADRB3 and metabolic disease: β3AR agonists and their possible use in combating metabolic disorders has previously been discussed elsewhere (Chen et al., 2020; Cypess et al., 2015; Marlatt & Ravussin, 2017; Michel et al., 2010; Schena & Caplan, 2019).